HGH Fragment the science.

Human growth hormone is a 191-amino-acid protein with distinct functional regions. Researchers identified that the lipolytic (fat-metabolizing) activity of GH could be localized to the C-terminal end of the molecule, leading to study of short peptides based on residues 176–191. The aim was to investigate this fat-metabolism activity separately from GH’s broader growth and IGF-1 effects.

The HGH Fragment 176–191 sequence is the direct parent of the modified analog AOD-9604, which carries an added tyrosine to improve stability. Both are used as research tools for studying GH-associated lipid metabolism. The material here is supplied strictly as a research peptide.

Research interest centers on the GH lipolytic domain:

• Lipolysis — the breakdown of stored triglycerides in fat cells, studied as a GH-domain activity that appears separable from glucose effects.
• Lipogenesis — reduced fat synthesis in some adipocyte models.
• Receptor independence — investigators have examined whether the fragment’s metabolic activity proceeds without classical GH-receptor growth signaling.

Work on the GH C-terminal fragment is preclinical, carried out mostly in rodent and cell-culture models, and overlaps heavily with the AOD-9604 literature:

• Metabolic studies (2000). Research characterized the synthetic lipolytic domain of human GH and its effects on lipid metabolism in laboratory models.
• Chronic-treatment models (2001). Studies in obese mice and beta-3-adrenergic-receptor knockout mice examined the fragment’s effects on fat metabolism after extended treatment.

These are observations in animals and cells. They do not establish human safety, dosing, or benefit.

The HGH Fragment 176–191 evidence base is preclinical; rigorous human clinical-trial data for the unmodified fragment is limited. No human safety, dosing, or efficacy is established here. The fragment is supplied strictly as a research material — for research use only, not for human or veterinary use.